Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
Before Prescribing Felbatol® (felbamate), the physician should be thoroughly familiar with the details of this prescribing information. FELBATOL® SHOULD NOT BE USED BY PATIENTS UNTIL THERE HAS BEEN A COMPLETE DISCUSSION OF THE RISKS AND THE PATIENT, PARENT, OR GUARDIAN HAS BEEN PROVIDED THE FELBATOL WRITTEN ACKNOWLEDGEMENT (SEE PATIENT/PHYSICIAN ACKNOWLEDGMENT FORM).
Medication labelWhy this: Advisory · dailymed-prescription
Felbatol® is not indicated as a first line antiepileptic treatment (see Warnings ). Felbatol® is recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk and has provided written acknowledgment, Felbatol® can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.
- generic_name
- felbamate
- product_names
- felbamate
- ndc
- 0037-0430, 0037-0430-01, 0037-0431, 0037-0431-01, 0037-0442, 0037-0442-67, 0037-0442-17
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en